All In Biotech

Investigational drug · Phase 2

TG4001

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for HPV-Related Carcinoma, HPV-Related Cervical Carcinoma, HPV-Related Anal Squamous Cell Carcinoma.

Phase 2

Last checked: Nov 19, 2026Latest source record: Feb 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

1

Any phase or sponsor naming "TG4001"

First trial start

2017

Sep 1, 2017

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "TG4001", any sponsor or status.

Conditions studied

As listed on its trial records.

  • HPV-Related Carcinoma
  • HPV-Related Cervical Carcinoma
  • HPV-Related Anal Squamous Cell Carcinoma
  • HPV-Related Penile Squamous Cell Carcinoma
  • HPV-Related Vulvar Squamous Cell Carcinoma

Approved drugs for the same conditions: Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "TG4001" as an intervention, largest first.

All trials
  • TransgeneIndustry

    NCT03260023 · 143 participants · Start Sep 1, 2017 · Primary completion Sep 18, 2024

    Drug: TG4001; Avelumab · For: HPV-Related Carcinoma; HPV-Related Cervical Carcinoma; HPV-Related Anal Squamous Cell Carcinoma and 2 more

    Sites: Jacksonville, Florida; Rochester, Minnesota; Angers, France · 20 sites in all

Newest research

PubMed records naming it or its code names, newest first.

All 3 on PubMed

Also in development for HPV-Related Carcinoma

  • PRGN-2009Phase 21 trial

    Precigen, Inc · Cervical Cancer, HPV-Related Carcinoma, HPV-Related Malignancy

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.